Phages that kill bacteria are seen as a possible solution to the waning power of antibiotics. But research funding is lacking and existing routes to approval and commercialisation are not suitable for these therapies, say UK MPs
A new analysis shows the US, China, UK, India and Australia all publish more papers on this pressing global health threat than any EU member state. More investment in novel therapies is needed, the report says
Phages are viruses that destroy bacteria and have the potential to supplement waning antibiotics. But researchers and entrepreneurs say the regulatory and funding environment is far from clear
By helping prevent, diagnose and manage bacterial infections, new medical technologies could curb overuse of antibiotics, slowing the spread of antimicrobial resistance
Investment in later stage clinical development is needed to back up recent improvements in the discovery of new antibiotics, and to ensure the use of novel products is managed to maintain their effectiveness
As member states push for a new research partnership on antimicrobial resistance, EU auditors say efforts to date have failed to reduce the threat to human health
Vaccines could offer hope - but who to vaccinate, and against what, has no clear answer yet. Read IMI Executive Director Dr Pierre Meulien’s perspective on what is needed to tackle antimicrobial resistance.
Armed with bear spray, microbiologist Naowarat ‘Ann’ Cheeptham is searching for hardy, less-studied bacteria that could play a role in stemming the antimicrobial resistance crisis
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.